XML 16 R5.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
Series A
Preferred Stock
Series D
Preferred Stock
Series E
Preferred Stock
Common Stock
Additional Paid-in Capital
Treasury Stock
Accumulated Deficit
Accumulated Other Comprehensive Income
Due from Shareholders
Total Onconetix Equity (Deficit)
Total
Balance at Dec. 31, 2024     $ 127,825,744 $ (625,791) $ (115,683,621) $ (2,723,397) $ (250,308) $ 8,542,627 $ 8,542,627
Balance (in Shares) at Dec. 31, 2024       27,684              
Balance (in Shares) at Dec. 31, 2024           (30)          
Issuance of common stock in connection with the ELOC     $ 1 4,776,308 250,308 5,026,617 5,026,617
Issuance of common stock in connection with the ELOC (in Shares)       58,838              
Stock-based compensation expense     29,256 29,256 29,256
Redemption of Series C Preferred Stock       (1,170,091) (1,170,091) (1,170,091)
Foreign currency translation adjustment       141,048 141,048 141,048
Changes in pension benefit obligation       (30,779) (30,779) (30,779)
Net loss       (8,545,885) (8,545,885) (8,545,885)
Balance at Mar. 31, 2025     $ 1 132,631,308 $ (625,791) (125,399,597) (2,613,128) 3,992,793 3,992,793
Balance (in Shares) at Mar. 31, 2025       86,522              
Balance (in Shares) at Mar. 31, 2025           (30)          
Balance at Dec. 31, 2024     127,825,744 $ (625,791) (115,683,621) (2,723,397) $ (250,308) $ 8,542,627 8,542,627
Balance (in Shares) at Dec. 31, 2024       27,684              
Balance (in Shares) at Dec. 31, 2024           (30)          
Balance at Dec. 31, 2025   $ 3 147,836,001 $ (625,791) (131,214,558) (231,028)     $ 15,764,627
Balance (in Shares) at Dec. 31, 2025   16,325 7,813 312,028              
Balance (in Shares) at Dec. 31, 2025           (30)         30
Stock-based compensation expense   22,305     $ 22,305
Conversion of Series E Preferred Stock to Common Stock   $ 1 (1)    
Conversion of Series E Preferred Stock to Common Stock (in Shares)     (232) 76,555              
Conversion of Series D Preferred Stock to Common Stock   $ 22 (22)    
Conversion of Series D Preferred Stock to Common Stock (in Shares)   (6,373)   2,222,656              
Issuance of Common Stock for Warrant Exercise   $ 1 384,841     384,842
Issuance of Common Stock for Warrant Exercise (in Shares)       144,087              
Cancellation of restricted common stock      
Cancellation of restricted common stock (in Shares)       (131)              
Cash in lieu of shares   (250)     (250)
Cash in lieu of shares (in Shares)       (11)              
Foreign currency translation adjustment   (210,172)     (210,172)
Net loss   (4,214,875)     (4,214,875)
Balance at Mar. 31, 2026   $ 27 $ 148,242,874 $ (625,791) $ (135,429,433) $ (441,200)     $ 11,746,477
Balance (in Shares) at Mar. 31, 2026   9,952 7,581 2,755,184              
Balance (in Shares) at Mar. 31, 2026           (30)         30